☰

Justin M. David, Ph.D. - Publications

Affiliations: 
2013 Department of Biological Sciences University of Delaware, Newark, DE, United States 
Area:
Cell Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Garman B, Jiang C, Daouti S, Kumar S, Mehta P, Jacques MK, Menard L, Manjarrez-Orduno N, Dolfi S, Mukherjee P, Rai SC, Lako A, Koenitzer JD, David JM. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Frontiers in Immunology. 14: 1151748. PMID 37795090 DOI: 10.3389/fimmu.2023.1151748  0.343
2020 Zeligs KP, Morelli MP, David JM, Neuman M, Hernandez L, Hewitt S, Ozaki M, Osei-Tutu A, Anderson D, Andresson T, Das S, Lack J, Abdelmaksoud A, Fantini M, Arlen PM, et al. Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer. Frontiers in Oncology. 10: 805. PMID 32637350 DOI: 10.3389/Fonc.2020.00805  0.556
2020 Fantini M, David JM, Annunziata CM, Morelli MP, Arlen PM, Tsang KY. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biotherapy & Radiopharmaceuticals. PMID 31928422 DOI: 10.1089/Cbr.2019.3141  0.563
2019 Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. Cancer Biotherapy & Radiopharmaceuticals. PMID 30601063 DOI: 10.1089/Cbr.2018.2628  0.39
2019 Arlen PM, Fantini M, David J, Annunziata CM, Tsang KY, Morelli P. Abstract 3947: Mechanisms of action of a neoantigen-targeting antibody NEO-201 Cancer Research. 79: 3947-3947. DOI: 10.1158/1538-7445.Am2019-3947  0.588
2018 Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells Cancer Research. 78: 619-619. DOI: 10.1158/1538-7445.Am2018-619  0.486
2018 David JM, Fantini M, Annunziata CM, Arlen PM, Tsang KY. Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway Cancer Research. 78: 3821-3821. DOI: 10.1158/1538-7445.Am2018-3821  0.587
2017 Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM. Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. Frontiers in Immunology. 8: 1899. PMID 29354121 DOI: 10.3389/Fimmu.2017.01899  0.529
2017 David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 6: e1349589. PMID 29123964 DOI: 10.1080/2162402X.2017.1349589  0.445
2017 Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. Jci Insight. 2. PMID 29093275 DOI: 10.1172/Jci.Insight.94296  0.491
2017 Shah SR, David JM, Tippens ND, Mohyeldin A, Martinez-Gutierrez JC, Ganaha S, Schiapparelli P, Hamilton DH, Palena C, Levchenko A, Quiñones-Hinojosa A. Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. Cell Reports. 21: 495-507. PMID 29020634 DOI: 10.1016/J.Celrep.2017.09.057  0.41
2017 Dominguez C, David JM, Palena C. Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Seminars in Cancer Biology. PMID 28823497 DOI: 10.1016/J.Semcancer.2017.08.002  0.515
2017 Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. Vaccine. PMID 28389098 DOI: 10.1016/J.Vaccine.2017.03.025  0.316
2017 Hamilton DH, David JM, Dominguez C, Palena C. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. Cells, Tissues, Organs. 203: 128-138. PMID 28214895 DOI: 10.1159/000446495  0.548
2017 Hamilton DH, Mathews-Griner L, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer F, Schlom J, Palena C. Abstract B64: A high-throughput screen identifies fulvestrant as an enhancer of immune-mediated cytotoxicity of mesenchymal-like lung cancer cells Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B64  0.506
2017 David JM, Schlom J, Lan Y, Palena C. Abstract 611: Reversion of mesenchymal features in NSCLC cells using M7824, a first-in-class bi-functional immunotherapeutic agent targeting PD-L1 and TGFβ1 (TGFβ TRAP) Cancer Research. 77: 611-611. DOI: 10.1158/1538-7445.Am2017-611  0.52
2016 David JM, Dominguez C, Palena C. Pharmacological and Immunological Targeting of Tumor Mesenchymalization. Pharmacology & Therapeutics. PMID 27916651 DOI: 10.1016/J.Pharmthera.2016.11.011  0.589
2016 David JM, Dominguez C, Hamilton DH, Palena C. The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines. 4. PMID 27348007 DOI: 10.3390/Vaccines4030022  0.473
2016 Hamilton DH, Matthews Griner L, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M, Palena C. Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27267852 DOI: 10.1158/1078-0432.Ccr-15-3059  0.56
2016 Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C. IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget. PMID 27248176 DOI: 10.18632/Oncotarget.9662  0.435
2016 David JM, Hamilton DH, Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology. 5: e1117738. PMID 27141403 DOI: 10.1080/2162402X.2015.1117738  0.624
2016 David JM, Dominguez CL, Schlom J, Palena C. Abstract 4032: Modulation of tumor PD-L1 expression by epithelial-mesenchymal phenotypic plasticity Cancer Research. 76: 4032-4032. DOI: 10.1158/1538-7445.Am2016-4032  0.534
2016 Shah S, David J, Tippens N, Mohyeldin A, Martinez JC, Ganaha S, Levchenko A, Palena C, Quinones-Hinojosa A. CSIG-05. PUTTING THE BRAKES ON BRACHYURY: IDENTIFYING AND TARGETING A CONSERVED TRANSCRIPTIONAL NETWORK THAT DRIVES PRIMARY AND METASTATIC TUMOR INITIATION AND PROPAGATION Neuro-Oncology. 18: vi41-vi41. DOI: 10.1093/Neuonc/Now212.166  0.384
2015 David JM, Rajasekaran AK. Gramicidin A: A New Mission for an Old Antibiotic. Journal of Kidney Cancer and Vhl. 2: 15-24. PMID 28326255 DOI: 10.15586/Jkcvhl.2015.21  0.417
2015 Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP, Jones FR, Schlom J. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget. PMID 26374823 DOI: 10.18632/oncotarget.5181  0.372
2015 David JM, Hamilton DH, Dominguez CL, Schlom J, Palena C. Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells Journal For Immunotherapy of Cancer. 3: 294. DOI: 10.1186/2051-1426-3-S2-P294  0.61
2015 Palena C, Hamilton DH, David JM, Dominguez C, Heery CR, Gulley JL, Schlom J. Abstract CN04-01: Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Cn04-01  0.532
2014 Sampson VB, David JM, Puig I, Patil PU, de Herreros AG, Thomas GV, Rajasekaran AK. Wilms' tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma. Plos One. 9: e102041. PMID 25025131 DOI: 10.1371/Journal.Pone.0102041  0.556
2014 David JM, Owens TA, Inge LJ, Bremner RM, Rajasekaran AK. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma. Molecular Cancer Therapeutics. 13: 788-99. PMID 24493697 DOI: 10.1158/1535-7163.Mct-13-0891  0.509
2014 Selvakumar P, Owens TA, David JM, Petrelli NJ, Christensen BC, Lakshmikuttyamma A, Rajasekaran AK. Epigenetic silencing of Na,K-ATPase β 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma. Epigenetics. 9: 579-86. PMID 24452105 DOI: 10.4161/Epi.27795  0.413
2014 David J, Hamilton D, Schlom J, Palena C. The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance Journal For Immunotherapy of Cancer. 2: 48. DOI: 10.1186/2051-1426-2-S3-P48  0.543
2013 David JM, Owens TA, Barwe SP, Rajasekaran AK. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells. Molecular Cancer Therapeutics. 12: 2296-307. PMID 24006494 DOI: 10.1158/1535-7163.Mct-13-0445  0.481
2013 David JM, Rajasekaran AK. Abstract 3451: Gramicidin-based nanopores induce cellular energy depletion and cell death in renal cell carcinoma. Cancer Research. 73: 3451-3451. DOI: 10.1158/1538-7445.Am2013-3451  0.393
2012 David JM, Rajasekaran AK. Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Research. 72: 2917-23. PMID 22659456 DOI: 10.1158/0008-5472.Can-11-3498  0.466
Show low-probability matches.